James N Marks

US Patent:

6492123, Dec 10, 2002

Filed:

Sep 3, 1998

Appl. No.:

09/146979

Inventors:

Kaspar-Philip Holliger - Cambridge, GB
Andrew David Griffiths - Cambridge, GB
Hendricus Renerus Jacobus Matheus Hoogenboom - Hasselt, BE
Magnus Malmqvist - Uppsala, SE
James David Marks - Kensington CA
Brian Timothy McGuinness - Cambridge, GB
Anthony Richard Pope - Cambridge, GB
Terence Derek Prospero - Cambridge, GB
Gregory Paul Winter - Cambridge, GB

Assignee:

Medical Research Council - London

International Classification:

G01N 3353

US Classification:

435 71, 5303871, 5303873, 4241351

Abstract:

Polypeptides comprising a first domain, which comprises a binding region of an immunoglobulin heavy chain variable region, and a second domain, which comprises a binding region of an immunoglobulin light chain variable region, the domains being linked but incapable of associating with each other to form an antigen binding site, associate to form antigen binding multimers, such as dimers, which may be multivalent or have multispecificity. The domains may be linked by a short peptide linker or may be joined directly together. Bispecific dimers may have longer linkers. Methods of preparation of the polypeptides and multimers and diverse repertoires thereof, and their display on the surface of bacteriophage for easy selection of binders of interest, are disclosed, along with many utilities.

US Patent:

6512097, Jan 28, 2003

Filed:

May 20, 1999

Appl. No.:

09/315574

Inventors:

James D. Marks - Kensington CA
Robert Schier - San Francisco CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C07K 1630

US Classification:

5303911, 5303873, 5303877, 5303881, 53038815, 5303882, 53038822, 53038824, 5303888, 53038885, 5303913, 5303917, 5303919, 530395

Abstract:

This invention provides novel chimeric molecules that specifically binds a tumor cell bearing a c-erbB-2. The chimeric molecules comprise an effector molecule attached to a C6 antibody that specifically binds to c-erbB-2. The chimeric molecules can specifically target and deliver effector molecules to cells overexpressing c-erb-B2.

US Patent:

6521404, Feb 18, 2003

Filed:

Nov 20, 1998

Appl. No.:

09/197224

Inventors:

Andrew David Griffiths - Cambridge, GB
Hendricus Renerus Jacobus Mattheus Hoogenboom - Cambridge, GB
James David Marks - Kensington CA
John McCafferty - Babraham, GB
Gregory Paul Winter - Cambridge, GB
Geoffrey Walter Grigg - Linley Point, AU

Assignee:

Medical Research Council - London
Cambridge Antibody Technology Limited - Cambridgeshire

International Classification:

C12Q 168

US Classification:

435 6, 435 5, 435 691, 435 697, 435 698, 435 911, 4352351, 4353201, 435DIG 1, 435DIG 4, 435DIG 14, 5303871, 5303873, 536 231, 536 234

Abstract:

Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.

US Patent:

6544731, Apr 8, 2003

Filed:

Nov 20, 1998

Appl. No.:

09/197221

Inventors:

Andrew David Griffiths - Cambridge, GB
Hendricus Renerus Jacobus Mattheus Hoogenboom - Cambridge, GB
James David Marks - Kensington CA
John McCafferty - Babraham, GB
Gregory Paul Winter - Trinity College, GB
Geoffrey Walter Grigg - Linley Point, AU

Assignee:

Medical Research Council - London
Cambridge Antibody Technology Limited - Cambridgeshire

International Classification:

C12N 700

US Classification:

435 6, 435 5, 435 691, 435 697, 435 698, 4352351, 4353201, 435DIG 1, 435DIG 4, 435DIG 14, 5303871, 5303873, 536 231, 536 234

Abstract:

Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.

US Patent:

6555313, Apr 29, 2003

Filed:

May 16, 2000

Appl. No.:

09/572392

Inventors:

Andrew David Griffiths - Cambridge, GB
Hendricus Renerus Jacobus Mattheus Hoogenboom - Cambridge, GB
James David Marks - Kensington CA
John McCafferty - Babraham, GB
Gregory Paul Winter - Cambridge, GB
Geoffrey Walter Grigg - Linley Point, AU

Assignee:

Medical Research Council - London
Cambridge Antibody Technology Limited - Cambridgeshire

International Classification:

C12Q 170

US Classification:

435 5, 435 6, 435 691, 435 697, 4353201, 435DIG 1, 435DIG 4, 435DIG 14, 435DIG 15, 435DIG 47, 435DIG 37, 5303871, 5303873, 536 231, 536 234, 536 2353

Abstract:

Methods are disclosed for the production of human self-antibodies and antibody fragments, which bind human antigens. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Human antibodies or antibody fragments are selected by binding with human antigens. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding to and is a human antigen. Nucleic acid libraries used may be derived from V-gene sequences of unimmunised humans. Part or all of the nucleic acid may be derived from oligonucleotide synthesis.

US Patent:

6582915, Jun 24, 2003

Filed:

Nov 28, 2000

Appl. No.:

09/723756

Inventors:

Andrew David Griffiths - Cambridge, GB
Hendricus Renerus Jacobus Mattheus Hoogenboom - Cambridge, GB
James David Marks - Kensington CA
John McCafferty - Babraham, GB
Gregory Paul Winter - Cambridge, GB
Geoffrey Walter Grigg - Linley Point, AU

Assignee:

Medical Research Council - London
Cambridge Antibody Technology Limited - Cambridgeshire

International Classification:

C12Q 168

US Classification:

435 6, 435 5, 435 691, 435 697, 435 911, 4352351, 4353201, 435DIG 1, 435DIG 4, 435DIG 14, 536 231, 5303873

Abstract:

Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.

US Patent:

6593081, Jul 15, 2003

Filed:

Mar 21, 2000

Appl. No.:

09/532840

Inventors:

Andrew David Griffiths - Cambridge, GB
Hendricus Renerus Jacobus Mattheus Hoogenboom - Cambridge, GB
James David Marks - Kensington CA
John McCafferty - Babraham, GB
Gregory Paul Winter - Cambridge, GB
Geoffrey Walter Grigg - Linley Point, AU

Assignee:

Medical Research Council - London
Cambridge Antibody Technology Limited - Cambridgeshire

International Classification:

C12O 170

US Classification:

435 5, 435 6, 435 691, 435 697, 4353201, 435DIG 1, 435DIG 4, 435DIG 14, 435DIG 15, 435DIG 47, 435DIG 37, 5303871, 5303873, 536 231, 536 234, 536 2353

Abstract:

Methods are disclosed for the production of human self-antibodies and antibody fragments, which bind human antigens. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Human antibodies or antibody fragments are selected by binding with human antigens. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding to and is a human antigen. Nucleic acid libraries used may be derived from V-gene sequences of unimmunised humans. Part or all of the nucleic acid may be derived from oligonucleotide synthesis.

US Patent:

6794128, Sep 21, 2004

Filed:

Feb 12, 1999

Appl. No.:

09/249529

Inventors:

James D. Marks - Kensington CA
Marie Alix Poul - San Francisco CA
Baltazar Becerril - Morelos, MX

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12Q 100

US Classification:

435 5, 435 4, 435 6, 435 71, 435 72, 4353201, 435DIG 1, 435DIG 2, 435DIG 3, 435DIG 4, 435DIG 14, 435DIG 15, 436501, 436518, 536 231, 536 2353

Abstract:

This invention provides methods of selecting antibodies that are internalized into target cells. The methods generally involve contacting target cells with one or more members of an antibody phage display library. The members of the phage display library are also contacted with cells of a subtractive cell line. The target cells are then washed to remove the subtractive cell line cells and members of the phage display library that are non-specifically bound or weakly bound to the target cells. The target cells are cultured under conditions where members of the phage display library can be internalized if bound to an internalizing marker and internalized members of the phage display library are then identified.